84,276 results match your criteria gynecological malignancies


Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells.

Acta Pharmacol Sin 2022 Jan 14. Epub 2022 Jan 14.

Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA.

Ovarian cancer is one of the most common gynecologic malignancies in women and has a poor prognosis. Taxanes are a class of standard first-line chemotherapeutic agents for the treatment of ovarian cancer. However, tumor-intrinsic and acquired resistance to taxanes poses major challenges to improving clinical outcomes. Read More

View Article and Full-Text PDF
January 2022

Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors.

J Immunol Res 2022 3;2022:5254911. Epub 2022 Jan 3.

Department of Gynecology and Obstetrics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.

Introduction: KLRB1 is a gene encoding CD161 expressed in NK cells and some T cell subsets. At present, KLRB1 is believed to affect tumorigenesis and development by regulating the cytotoxicity of NK cells in several cancers. However, there is a lack of systematic reviews of KLRB1 in a variety of malignancies. Read More

View Article and Full-Text PDF
January 2022

The Pretreatment Controlling Nutritional Status Score in Ovarian Cancer: Influence on Prognosis, Surgical Outcome, and Postoperative Complication Rate.

Geburtshilfe Frauenheilkd 2022 Jan 10;82(1):59-67. Epub 2022 Jan 10.

Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Gynecologic Cancer Unit, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

The Controlling Nutritional (CONUT) Status score is an established predictor of impaired prognosis in patients with solid tumors. The aim of this study was to investigate the prognostic value of the CONUT score for overall survival and perioperative complication rates in patients with epithelial ovarian cancer. In this retrospective study we assessed the data of 337 consecutive patients with ovarian cancer. Read More

View Article and Full-Text PDF
January 2022

Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2018 and Annual Treatment Report for 2013.

J Obstet Gynaecol Res 2022 Jan 13. Epub 2022 Jan 13.

Department of Gynecology and Obstetrics, Tohoku University Graduate School of Medicine, Sendai, Japan.

To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2018 and the Annual Treatment Report for 2013, on the outcomes of patients who started treatment in 2013. The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2018 were analyzed retrospectively. Read More

View Article and Full-Text PDF
January 2022

Vasohibin-1 and -2 in pulmonary lymphangioleiomyomatosis (LAM) cells associated with angiogenic and prognostic factors.

Pathol Res Pract 2022 Jan 7;230:153758. Epub 2022 Jan 7.

Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan; Department of Pathology, Tohoku University Hospital, Sendai, Miyagi, Japan. Electronic address:

Lymphangioleiomyomatosis (LAM) is a rare pulmonary neoplasm, clinically associated with dyspnea and respiratory failure. Current therapeutic modalities do not necessarily reach satisfactory outcome and novel therapeutic approaches are currently warranted. Therefore, in this study, we focused on vasohibin-1 (VASH1) and -2 (VASH2); VASH1 terminated and VASH2 promoted angiogenesis. Read More

View Article and Full-Text PDF
January 2022

SERPINB3 (SCCA1) inhibits cathepsin L and lysoptosis, protecting cervical cancer cells from chemoradiation.

Commun Biol 2022 Jan 12;5(1):46. Epub 2022 Jan 12.

Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO, 63110, USA.

The endogenous lysosomal cysteine protease inhibitor SERPINB3 (squamous cell carcinoma antigen 1, SCCA1) is elevated in patients with cervical cancer and other malignancies. High serum SERPINB3 is prognostic for recurrence and death following chemoradiation therapy. Cervical cancer cells genetically lacking SERPINB3 are more sensitive to ionizing radiation (IR), suggesting this protease inhibitor plays a role in therapeutic response. Read More

View Article and Full-Text PDF
January 2022

Benign multicystic peritoneal mesothelioma in a postmenopausal woman complicated with an ovarian cyst: a case report.

Pan Afr Med J 2021 19;40:171. Epub 2021 Nov 19.

Department of Obstetrics and Gynecology, University Hospital of Larissa, Larissa, Thessaly, Greece.

Benign multicystic peritoneal mesothelioma is a rare cystic neoplasm, characterized by subtle symptoms, that occurs predominantly in reproductive-aged women. The pathogenesis and etiology of the disease are yet to be determined. We herein present a 71-year-old woman presented to our clinic with persistent low back pain. Read More

View Article and Full-Text PDF
January 2022

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.

J Immunother Cancer 2022 Jan;10(1)

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

Background: Combination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian cancer (ROC). We report the results of camrelizumab (an anti-programmed cell death protein-1 antibody) in combination with famitinib (a receptor tyrosine kinase inhibitor) for the treatment of platinum-resistant ROC from an open-label, multicenter, phase 2 basket trial.

Methods: Eligible patients with platinum-resistant ROC were enrolled to receive camrelizumab (200 mg every 3 weeks by intravenous infusion) and oral famitinib (20 mg once daily). Read More

View Article and Full-Text PDF
January 2022

Identification and validation of the high expression of pseudogene TCAM1P in cervical cancer via integrated bioinformatics analysis.

Cancer Cell Int 2022 Jan 11;22(1):17. Epub 2022 Jan 11.

Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou Key Laboratory of Cervical Diseases, No. 7, Front Kangfu Street, Zhengzhou, 450052, Henan, People's Republic of China.

Background: HPV as the main cause of cervical cancer has long been revealed, but the detailed mechanism has not yet been elucidated. The role of testis/cancer antigen in cervical cancer has been revealed. However, there are no reports about the statement of testis/cancer-specific non-coding RNA. Read More

View Article and Full-Text PDF
January 2022

LncRNA HCG11 represses ovarian cancer cell growth via AKT signaling pathway.

J Obstet Gynaecol Res 2022 Jan 11. Epub 2022 Jan 11.

Department of Gynecology and Obstetrics, Ningbo Yinzhou Second Hospital, Ningbo, Zhejiang, China.

Aim: Ovarian cancer is a main contributor of cancer-relevant deaths among women worldwide due to high incidence and mortality. Mounting evidence has unveiled that lncRNAs play critical roles in malignancies, including ovarian cancer. Although the tumor suppressor function of HCG11 in prostate cancer and glioma has been proved, investigations on HCG11 role in ovarian cancer are still scarce. Read More

View Article and Full-Text PDF
January 2022

Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.

Trials 2022 Jan 10;23(1):29. Epub 2022 Jan 10.

Department of Gynecology and Obstetrics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, People's Republic of China.

Background: Currently, the standard treatment for locally advanced cervical cancer is concurrent chemoradiation (CCRT). The effect of neoadjuvant chemotherapy in advanced cervical cancer is controversial. Studies have shown that the addition of a weekly regimen of neoadjuvant chemotherapy (NACT) followed by CCRT may be superior to a thrice-weekly regimen of NACT and CCRT. Read More

View Article and Full-Text PDF
January 2022

LINC00885 promotes cervical cancer progression through sponging miR-3150b-3p and upregulating BAZ2A.

Biol Direct 2022 Jan 10;17(1). Epub 2022 Jan 10.

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanchang University, No. 17 Yong Wai Main Street, Nanchang, Jiangxi, China.

Background: Cervical cancer (CC) is one of the most common malignancies affecting female worldwide. Long non-coding RNAs (lncRNAs) are increasingly indicated as crucial participants and promising therapeutic targets in human cancers. The main objective of this study was to explore the functions and mechanism of LINC00885 in CC. Read More

View Article and Full-Text PDF
January 2022

Multiple Primary Malignancies in Patients with Gynecologic Cancer.

J Clin Med 2021 Dec 26;11(1). Epub 2021 Dec 26.

Department of Obstetrics and Gynecology, KonKuk University Hospital, Seoul 05030, Korea.

Objective: To investigate the prevalence and oncologic outcomes of patients with multiple primary malignant tumors (MPMT) with gynecologic cancer.

Methods: This retrospective study included 1929 patients diagnosed with gynecologic cancer at a tertiary medical center between August 2005 and April 2021. The clinical data included cancer location, age at primary malignancy diagnosis, interval between primary and secondary cancer, stage of cancer, family history of cancer, genetic testing, dates of last follow-up, recurrence, and death. Read More

View Article and Full-Text PDF
December 2021

Three-Dimensional Genome Organization in Breast and Gynecological Cancers: How Chromatin Folding Influences Tumorigenic Transcriptional Programs.

Cells 2021 Dec 28;11(1). Epub 2021 Dec 28.

Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, Mexico City 03100, Mexico.

A growing body of research on the transcriptome and cancer genome has demonstrated that many gynecological tumor-specific gene mutations are located in cis-regulatory elements. Through chromosomal looping, cis-regulatory elements interact which each other to control gene expression by bringing distant regulatory elements, such as enhancers and insulators, into close proximity with promoters. It is well known that chromatin connections may be disrupted in cancer cells, promoting transcriptional dysregulation and the expression of abnormal tumor suppressor genes and oncogenes. Read More

View Article and Full-Text PDF
December 2021

Essentiality of Trace Elements in Pregnancy, Fertility, and Gynecologic Cancers-A State-of-the-Art Review.

Nutrients 2021 Dec 31;14(1). Epub 2021 Dec 31.

Chair and Department of Anatomy, Medical University of Lublin, ul. Jaczewskiego 4, 20-090 Lublin, Poland.

Gynecological neoplasms pose a serious threat to women's health. It is estimated that in 2020, there were nearly 1.3 million new cases worldwide, from which almost 50% ended in death. Read More

View Article and Full-Text PDF
December 2021

Effect of Polymorphisms of ABCB1 and MTHFR on Methotrexate-Related Toxicities in Adults With Hematological Malignancies.

Front Oncol 2021 24;11:759805. Epub 2021 Dec 24.

Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Study of the association between single nucleotide polymorphisms (SNPs) of methotrexate (MTX) pathway genes and MTX-related toxicity in the treatment of hematological malignancies is popular. Here, we studied the association between SNPs of MTHFR and ABCB1 and MTX-related toxicity in 157 adult Chinese patients diagnosed with hematological malignancies. Patients were genotyped for MTHFR rs1801131, MTHFR rs1801133, and ABCB1 rs1045642 by fluorescence hybridization. Read More

View Article and Full-Text PDF
December 2021

Implementing community-based human papillomavirus self-sampling with SMS text follow-up for cervical cancer screening in rural, southwestern Uganda.

J Glob Health 2021 25;11:04036. Epub 2021 Dec 25.

Harvard Medical School, Boston, MA, USA.

Background: Self-collected HPV screening may improve cervical cancer screening coverage in low resource countries, yet data guiding implementation and follow-up of abnormal results are sparse.

Methods: This is a prospective cohort implementation study of HPV self-testing program in Mbarara, Uganda with mobile phones to facilitate result notification and referral for treatment at a regional hospital. The effectiveness of the interventions was analyzed using Proctor's model of implementation. Read More

View Article and Full-Text PDF
January 2022

Case Report: Vaccination by Autologous CD16 Dendritic Cells and Anti-PD-L 1 Antibody Synergized With Radiotherapy To Boost T Cells-Mediated Antitumor Efficacy In A Psoriatic Patient With Cutaneous Squamous Cell Carcinoma.

Front Immunol 2021 23;12:752563. Epub 2021 Dec 23.

Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, Taipei, Taiwan.

The combination of radiotherapy and immunotherapy improves the survival rate of patients with malignancies developed through escape from T-cell-mediated immune surveillance. Immune checkpoint inhibitors, such as anti-programmed cell death protein-ligand 1 (anti-PD-L1) antibody, are used to rescue exhausted T cells. Simultaneously, dendritic cells (DCs) which are antigen-presenting cells that can initiate T-cell activation, are used to induce a tumor-specific immune response. Read More

View Article and Full-Text PDF
December 2021

Factors Affecting the Histopathological Outcomes of Atypical Glandular Cells on Pap Test.

J Cytol 2021 Oct-Dec;38(4):210-215. Epub 2021 Nov 12.

Department of Pathology, Zeynep Kamil Training and Research Hospital, University of Health Sciences, Turkey.

Background: Glandular cell abnormalities may indicate the presence of pre-malignant or malignant lesions.

Aim: This study aimed to investigate the relationship between atypical glandular cells (AGC) and patients' demographics, histopathological outcomes, Human Papillomavirus (HPV) test results.

Material And Methods: Between January 2015 and December 2019, women with AGC on Pap tests were retrieved from the hospital electronic database. Read More

View Article and Full-Text PDF
November 2021

Should Liquid Based Cytology (LBC) be Applied to Thyroid Fine Needle Aspiration Cytology Samples?: Comparative Analysis of Conventional and LBC Smears.

J Cytol 2021 Oct-Dec;38(4):198-202. Epub 2021 Nov 12.

Department of Cytology and Gynecological Pathology, Histopathology, Otolaryngology and Head and Neck Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Context: Liquid-based cytology (LBC) is a cyto-preparatory technique that may be applied to fine-needle aspiration (FNA) samples. However, its efficacy over conventional smears (CS) in thyroid is controversial.

Aims: The aim of this study was to compare CS versus LBC (SurePath, BD) preparations in thyroid FNA samples for diagnostic efficacy. Read More

View Article and Full-Text PDF
November 2021

Synchronous/metachronous endometrial and colorectal malignancies in Taiwanese women: a population-based nationwide study.

Arch Gynecol Obstet 2022 Jan 10. Epub 2022 Jan 10.

Biostatistics Unit, Clinical Trial Center, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Introduction: Endometrial cancer (EC) and colorectal cancer (CRC) may share a common genetic background. In a subset of patients, the two malignancies can coexist either at the time of diagnosis (synchronous) or develop consequently (metachronous). The purpose of this nationwide, population-based study was to investigate the occurrence and clinical outcomes of synchronous/metachronous EC/CRC in Taiwanese women. Read More

View Article and Full-Text PDF
January 2022

Creating work environments where people of all genders in gynecologic oncology can thrive: An SGO evidence-based review.

Gynecol Oncol 2022 Jan 6. Epub 2022 Jan 6.

Gynecologic Oncology for the Mount Sinai Health System, Icahn School of Medicine at Mount Sinai and the Blavatnik Family Women's Health Research Institute, New York, NY, USA. Electronic address:

Equality, equity, and parity in the workplace are necessary to optimize patient care across all aspects of medicine. Gender-based inequities remain an obstacle to quality of care, including within the now majority women subspecialty of gynecologic oncology. The results of the 2020 SGO State of the Society Survey prompted this evidence-based review. Read More

View Article and Full-Text PDF
January 2022

Validation of the 2021 FIGO staging schema for advanced vulvar cancer.

Int J Gynecol Cancer 2022 Jan 7. Epub 2022 Jan 7.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Objective: The International Federation of Gynecology and Obstetrics (FIGO) revised the vulvar cancer staging schema in 2021. Previous stage IIIA-B diseases were reclassified based on nodal size (≤5 mm for stage IIIA compared with >5 mm for stage IIIB), and previous stage IVA1 disease based on non-osseous organ extension was reclassified to stage IIIA whereas osseous extension remained as stage IVA. This study sought to validate the 2021 FIGO vulvar cancer staging schema. Read More

View Article and Full-Text PDF
January 2022

Bilateral renal metastases from extraskeletal mesenchymal chondrosarcoma of thigh.

BMJ Case Rep 2022 Jan 7;15(1). Epub 2022 Jan 7.

Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Mesenchymal chondrosarcoma (MC) is a rare cartilaginous tumour that occurs in the extraskeletal locations in about one-third of cases. It is aggressive in behaviour and may involve the lower extremities, central nervous system or spine. Mesenchymal tumours are known for distant metastasis; however, metastasis to bilateral kidneys after treatment has not been reported earlier. Read More

View Article and Full-Text PDF
January 2022

High Grade Serous Ovarian Carcinoma in a Liver Transplant Recipient Patient: A Case Report and Review of Literature.

Transplant Proc 2022 Jan 4. Epub 2022 Jan 4.

Department of Gynecologic Oncology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.

According to GLOBOCAN 2020 data, the incidence of ovarian cancer is 1.6%. Ovarian cancer ranks 19th in incidence and 15th in mortality with a rate of 2. Read More

View Article and Full-Text PDF
January 2022

Uterine extension determined by MRI: a useful parameter for differentiating subserosal leiomyomas from ovarian tumors.

Abdom Radiol (NY) 2022 Jan 7. Epub 2022 Jan 7.

Department of Radiology, Gifu University, 1-1 Yanagido, Gifu, 501-1194, Japan.

Purpose: This study aimed to evaluate the utility of uterine extension determined via MRI for the differentiation of large subserosal leiomyomas from ovarian tumors.

Methods: In total, 55 patients with subserosal leiomyomas and 127 patients with ovarian tumors were included in this study. These patients were selected from a cohort of female patients whose pelvic masses were larger than 10 cm and who underwent preoperative MRI. Read More

View Article and Full-Text PDF
January 2022

ARID1A-mutated cervical cancer depends on the activation of YAP signaling.

Front Biosci (Landmark Ed) 2021 12;26(12):1411-1421

Department of Obstetrics and Gynecology, The 2nd Affiliated Hospital of Harbin Medical University, 150081 Harbin, Heilongjiang, China.

Background: Cervical cancer is a prevalent female malignancy with poor survival rates. ARID1A is frequently mutated or deleted in a variety of tumors and YAP signaling is widely activated in human malignancies. Nevertheless, the mechanism of YAP signaling in ARID1A-mutated cervical cancer remains unknown. Read More

View Article and Full-Text PDF
December 2021

Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer.

Arch Gynecol Obstet 2022 Jan 7. Epub 2022 Jan 7.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, 161 Fort Washington Ave, Suite 456, New York, NY, 10032, USA.

Purpose: We used real-world claims data to assess the utility of the relatively novel therapeutic bevacizumab in patients with newly diagnosed ovarian cancer in the United States after release of clinical data but prior to FDA approval.

Methods: We used the IQVIA Pharmetrics Plus commercial claims database to identify women with a new diagnosis of ovarian cancer who underwent primary surgery or neoadjuvant chemotherapy followed by interval surgery from 2006 to 2018. We calculated the rate of use of bevacizumab, and the relative frequency of hospital and emergency department (ED) admissions. Read More

View Article and Full-Text PDF
January 2022

The Circadian Gene NPAS2 Act as a Putative Tumor Stimulative Factor for Uterine Corpus Endometrial Carcinoma.

Cancer Manag Res 2021 22;13:9329-9343. Epub 2021 Dec 22.

Department of Obstetrics and Gynecology, Ningbo First Hospital, Ningbo, Zhejiang, 315035, People's Republic of China.

Background: Mounting evidence indicates altered circadian rhythm represents a critical factor affecting carcinogenesis and tumor progression. The circadian gene neuronal PAS domain protein 2 (NPAS2) constitutes a newly discovered prognostic biomarker. NPAS2 dysregulation is found in multiple malignancies, although its functions in uterine corpus endometrial carcinoma (UCEC) remain largely unknown. Read More

View Article and Full-Text PDF
December 2021

Neuroendocrine Carcinoma of the Endometrium with Ectopic Secretion of Parathyroid Hormone Presenting as Hypercalcemia- Related Posterior Reversible Encephalopathy syndrome: A Case Report.

Acta Neurol Taiwan 2022 Jan;31(1):36-40

Department of Neurology, Tri-Service General Hospital; and School of Medicine, National Defense Medical Center, Taipei, Taiwan, Republic of China.

Purpose: Posterior reversible encephalopathy syndrome (PRES) displayed various acute neurological symptoms. PRES is a rare presentation of hypercalcemia. Here we present a case with ectopic secretion of parathyroid hormone from neuroendocrine carcinoma of the endometrium presenting as hypercalcemia-related PRES. Read More

View Article and Full-Text PDF
January 2022